GF CSI Innovative Drugs Industry ETF(515120) Falls 0.79% in Morning Trading, Attracting RMB 459 Million Over Past 4 Days

NewTimeSpace News — As of 10:34 on April 20, 2026, GF Innovative Drug ETF (515120) fell 0.79%, with the latest price at RMB 0.63. Looking at a longer time horizon, as of April 17, 2026, the ETF had cumulatively increased 6.18% over the past month, ranking 3rd out of 7 comparable funds in terms of gains. (The stocks listed above are index constituents only, with no specific recommendation intended.)

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 1.81% and trading volume of RMB 167 million. Extending the timeframe, as of April 17, the ETF's average daily trading volume reached RMB 487 million over the past week, placing it in the top 2 among comparable funds.

Regarding scale, GF Innovative Drug ETF's latest assets under management stood at RMB 9.284 billion, hitting a new high for the past year and ranking 2nd out of 7 comparable funds. (Data Source: Wind)

In terms of shares outstanding, the ETF increased by 718 million shares over the past week, marking substantial growth and ranking 1st out of 7 comparable funds in new share additions. (Data Source: Wind)

From the perspective of net capital inflows, GF Innovative Drug ETF has recorded consecutive net inflows over the past 4 days, with a peak single-day inflow of RMB 244 million, totaling RMB 459 million in "capital attraction," with an average daily net inflow of RMB 115 million. (Data Source: Wind)

Data indicates continued positioning by leveraged funds. GF Innovative Drug ETF has recorded net margin purchases for 9 consecutive days, with a peak single-day net purchase of RMB 16.568 million, and the latest margin balance at RMB 323 million. (Data Source: Wind)

As of April 17, GF Innovative Drug ETF has risen 27.04% in net asset value over the past 2 years. In terms of return capability, as of April 17, 2026, since its inception, the ETF's highest monthly return was 23.00%, with the longest consecutive rising streak lasting 5 months and a maximum consecutive gain of 32.68%. The average monthly return during rising months was 5.63%. As of April 17, 2026, the ETF has achieved an annualized excess return over the benchmark of 0.86% over the past 2 years.

Regarding drawdown, as of April 17, 2026, the ETF's drawdown relative to the benchmark this year was 0.14%, representing lower drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF charges a management fee of 0.50% and a custody fee of 0.10%.

Regarding tracking accuracy, as of April 17, 2026, the ETF's tracking error since the beginning of this year was 0.009%, representing the highest tracking precision among comparable funds.

From a valuation perspective, the CSI Innovative Drug Industry Index tracked by GF Innovative Drug ETF currently has a price-to-earnings ratio (PE-TTM) of only 42.72x, standing at the 1.91st percentile over the past year, meaning the valuation is lower than 98.09% of the time over the past year, placing it at a historical low.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 most representative listed companies whose main business involves innovative drug research and development as index constituents, to reflect the overall performance of securities of companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.